On Tuesday, in the course of current trade, Shares of QEP Resources Inc (NYSE:QEP), climbed 3.83%, and is now trading at $13.54.
QEP Resources, stated second quarter 2015 financial and operating results. The Company stated a net loss from ongoing operations of $76.3 million, or $0.43 per diluted share, for the second quarter 2015 contrast with a net loss from ongoing operations of $106.1 million, or $0.59 per diluted share, in the second quarter 2014.
Net income or loss comprises non-cash gains and losses associated with the change in the fair value of derivative instruments, gains and losses from asset sales, a non-cash pension curtailment expense and impairment charges. Not taking into account these items, the Company’s second quarter 2015 Adjusted Net Income (a non-GAAP measure) was $16.0 million, or $0.09 per diluted share, contrast with Adjusted Net Income from ongoing operations of $54.1 million, or $0.30 per diluted share, for the comparable 2014 period. The decrease in Adjusted Net Income was due primarily to significantly lower average field-level prices for crude oil, natural gas and NGL, partially offset by higher crude oil volumes, lower production taxes and higher proceeds from realized commodity derivatives.
QEP Resources, Inc., through its auxiliaries, operates as an exploration and production company. The company acquires, explores, develops, and produces natural gas, oil, and natural gas liquids (NGLs) primarily in the Pinedale Anticline in western Wyoming; the Williston Basin in North Dakota; the Uinta Basin in eastern Utah; the Permian Basin in western Texas; the Haynesville/Cotton Valley in northwestern Louisiana; and other proven properties in Wyoming, Utah, and Colorado.
During an Afternoon trade, Shares of Bristol-Myers Squibb Co (NYSE:BMY), dipped -0.60%, and is now trading at $64.96.
Bristol-Myers Squibb Company, declared a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need assist paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis and monitoring of CML. The donation will also support LLS CML awareness activities focused on educating patients, caregivers and healthcare providers about the importance of continued monitoring with PCR testing.
“Routine PCR testing is critical because oncologists rely on the results to determine their patients’ clinical status of early and ongoing response to CML treatment and to assist detect when patients are potentially becoming resistant to treatment, which may allow for earlier intervention,” said Louis J. DeGennaro, LLS’s president and CEO. “Research indicates that early response to treatment and careful monitoring correlate with better overall survival rates.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, ACCO Brands Corporation (NYSE:ACCO) , gained 0.13% Tuesday.
ACCO Brands Corporation, stated its second quarter results for the period ended June 30, 2015.
“Our better-than-predictable results in the second quarter were due to strong operational performance and improved sales trends across our business,” said Boris Elisman, president and chief executive officer, ACCO Brands. “Ongoing expense discipline and productivity improvements assisted offset the challenging currency environment. After a good first half, we are raising our full-year adjusted earnings-per-share guidance to $0.75-$0.78.”
ACCO Brands Corporation manufactures and markets office, school, and calendar products, and select computer and electronic accessories primarily in the Unites States, Northern Europe, Brazil, Canada, Australia, and Mexico.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
